Skip to content

Insider · CIK 0001827198

Adam Laponis

cfoofficer

Files at TWST (Twist Bioscience Corp). First filing Oct 11, 2024, latest Oct 5, 2026.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $1.9M sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

TWST: Twist Bioscience Corp

TWSTOct 9, 2026 · close 159.78

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
62Notable
TWSTsell 6
Twist Bioscience Corp
$1.5M
8,057 shares
-7%+641% from low-2% from high
49Moderate
TWSTsell 7
Twist Bioscience Corp
$186k
4,160 shares
-4%-
49Moderate
TWSTsell 7
Twist Bioscience Corp
$186k
4,160 shares
-4%-
36Weak
TWSTsell 2
Twist Bioscience Corp
$36k
856 shares
-1%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Oct 2, 2026TWST
Twist Bioscience Corp
SOpen-market sale
Common Stock
-8,057$188.88$1.5M100,5767 d ago
Dec 4, 2024TWST
Twist Bioscience Corp
AGrant or award
Common Stock
+26,745$0.00$0115,982Dec 6, 2024
Nov 6, 2024TWST
Twist Bioscience Corp
SOpen-market sale
Common Stock
-4,160$44.61$186k89,237Nov 15, 2024
Nov 6, 2024TWST
Twist Bioscience Corp
SOpen-market sale
Common Stock
-4,160$44.61$186k89,237Nov 8, 2024
Nov 4, 2024TWST
Twist Bioscience Corp
AGrant or award
Common Stock
+20,000$0.00$093,397Nov 6, 2024
Oct 9, 2024TWST
Twist Bioscience Corp
SOpen-market sale
Common Stock
-856$41.81$36k73,397Oct 11, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Adam Laponis: insider trades and track record | InsiderTell